MELBOURNE, Australia, Feb. 27, 2018 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD). [Read more…]
Nikon & ACTE Invest in Regenerative Medicine Products from Dental Pulp Cells
Nikon enters into a business alliance to establish a clinical-use master cell bank, to be utilized for regenerative medicine products derived from dental pulp cells for the first time in Japan.
January 29, 2018 – Nikon Corporation (Kazuo Ushida, President, Tokyo) has announced a business alliance agreement (hereinafter referred to as the “agreement”) with Advanced Cell Technology and Engineering Ltd. (Koichi Otomo, President, Tokyo, hereinafter referred to as “ACTE”) in order to establish a clinical-use master cell bank (MCB)*1, to be employed for regenerative medicine products derived from dental pulp cells*2. [Read more…]
Advances in in-vitro Science are Translating to Human Outcomes with Patrick Dentinger, President & CEO
I had the honor of interviewing Patrick Dentinger, President and CEO of ACF Bioservices, an Absorption Systems company whose mission is to develop innovative research tools that can be used to accurately predict human outcomes. The company has facilities in Philadelphia, PA, Medford, MA, San Diego, CA, and Panama City, Panama.
In this fascinating interview, we discuss Mr. Dentinger’s background, the establishment of ACF, its origins in parent company Absorption Systems, and the critical role it is playing within the rapidly expanding cell- and gene-therapy industry. [Read more…]
Eppendorf Hosts Second Stem Cell Community Day in Duesseldorf
Hamburg/Juelich, January 22, 2018 – The second international Stem Cell Community Day will take place on April 24, 2018 in Duesseldorf, Germany. The event brings together experts from industry and academia to discuss recent trends, achievements, and challenges in bioprocessing technologies for stem cell research. The conference is organized by leading life science company Eppendorf AG.
In three sessions, the participants will discuss ways for establishing robust stem cell culture protocols, process strategies for obtaining commercial cell quantities, and challenges related to product purity. Professor Joaquim M. S. Cabral from the University of Lisbon will chair the conference. Dr. Robert Zweigerdt from Hannover Medical School and Karen Coopman, PhD from Loughborough University will present their latest findings in keynote lectures.
“During the first Stem Cell Community Day in 2017 our speakers presented cutting-edge research and we greatly enjoyed the first-hand insights and lively discussions,” reviews Dr. Karl Rix, Head of Business Unit Bioprocess at Eppendorf. “The enormously positive feedback from the participants motivated us to go to the next round.”
All participants are invited to present their work during the poster session. A scientific committee will award three poster prizes. Abstract submission is open until March 19, 2018. To submit an abstract and to register please visit www.stemcellday.de. On the same website, interested persons find information on the program and the venue, as well as impressions of the first Stem Cell Community Day in 2017. The conference language is English. [Read more…]
Hemostemix Signs License Agreement with Aspire Health Science for ACP-01
Calgary, Alberta, Feb. 23, 2018 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce it has finalized the terms of a license agreement (the “License Agreement”) with Aspire Health Science, LLC (“Aspire”) for the Company’s lead therapeutic product technology, ACP-01. ACP-01 is currently the subject of a U.S. Food and Drug Administration (FDA) and Health Canada approved Phase II clinical trial for patients with critical limb ischemia (CLI).
Aspire is an Orlando, Florida based private company focused on the field of stem cell manufacturing as well as related research and development utilizing state-of-the-art FDA cGMP (Current Good Manufacturing Practices) certified laboratory facilities in Orlando, Florida. As previously announced, the Company also recently finalized the terms of a contract manufacturing services agreement (the “Manufacturing Agreement”) with Aspire, formalizing the transition of the Company’s stem cell manufacturing operations from Company owned facilities in Israel to Aspire’s Orlando, Florida facilities. [Read more…]
- « Previous Page
- 1
- …
- 241
- 242
- 243
- 244
- 245
- …
- 338
- Next Page »